Maximum quantity allowed is 999
Please select the quantity
CAS RN: 143664-11-3 | Product Number: E1371
Elacridar

Purity: >98.0%(HPLC)
Synonyms:
- N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide
Product Documents:
Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
![]() |
---|---|---|---|---|---|
25MG |
NT$6,216
|
11 | 0 | Contact Us | |
100MG |
NT$18,732
|
35 | 1 | Contact Us |
* The above prices include freight cost, customs, and other charges to the destination except for products that need to be shipped by sea or dry ice. For details, please contact
our distributor
in Taiwan to order our product.
* The storage conditions are subject to change without notice.
Product Number | E1371 |
Purity / Analysis Method | >98.0%(HPLC) |
Molecular Formula / Molecular Weight | C__3__4H__3__3N__3O__5 = 563.65 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Frozen (<0°C) |
Condition to Avoid | Heat Sensitive |
Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image), 25MG-Glass Bottle with Plastic Insert (View image) |
CAS RN | 143664-11-3 |
Reaxys Registry Number | 7324887 |
PubChem Substance ID | 468591739 |
MDL Number | MFCD00912604 |
Specifications
Appearance | White to Yellow to Green powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Properties (reference)
Melting Point | 210 °C |
GHS
Hazard Statements | H413 : May cause long lasting harmful effects to aquatic life. |
Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. |
Related Laws:
RTECS# | AR7621300 |
Transport Information:
H.S.code* | 2933.99-000 |
Application
Elacridar: A Potent Dual Inhibitor of Breast Cancer Resistance Protein (BCRP) and P-Glycoprotein (P-gp)
Elacridar (GF120918) is a potent dual inhibitor of breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp). BCPR is a member of ATP-binding cassette family of drug transporters. P-gp, known as multidrug resistance protein 1 (MDR1), is an ATP-binding protein of the cell membrane that pumps many foreign substances out of cells. Therefore, it is believed that elacridar increases oral bioavailability of topotecan, a topoisomerase inhibitor. (The product is for research purpose only.)
References
- In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
- Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
- Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies (a review)
- Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.